Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of azacitidine + valproic acid with optional tretinoin in high-risk myelodysplastic syndrome
2005-004811-31Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Nov 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine, valproic acid and tretinoin in myelodysplastic syndrome (MDS) (2 arms), sponsored by GIMEMA. Primary endpoint: Complete or partial remission rate. Started Nov 2006; status: completed.
02
Drugs
azacitidinevalproic acidtretinoin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-004811-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004811-31.